Hepatitis C virus and risk of non-Hodgkin lymphoma in British Columbia, Canada

✍ Scribed by John J. Spinelli; Agnes S. Lai; Mel Krajden; Anton Andonov; Randy D. Gascoyne; Joseph M. Connors; Angela R. Brooks-Wilson; Richard P. Gallagher

• Publisher: John Wiley and Sons
• Year: 2007
• Tongue: French
• Weight: 73 KB
• Volume: 122
• Category: Article
• ISSN: 0020-7136
• DOI: 10.1002/ijc.23105

✦ Synopsis

Abstract

We investigated Hepatitis C virus (HCV) seropositivity and the risk of non‐Hodgkin lymphoma (NHL) in a population‐based case‐control study in British Columbia, Canada. Cases were aged 20–79, diagnosed between March 2000 and February 2004, and resident in greater Vancouver or Victoria. Cases with HIV or a prior transplant were excluded. Controls were chosen from the Client Registry of the British Columbia (BC) Ministry of Health, and were age/sex/region frequency matched to cases. Antibodies for HCV were measured in 795 cases and 697 control subjects. HCV seropositivity was 2.4% in cases and 0.7% in controls [odds ratio (OR) = 2.6, 95% confidence interval (CI) = 0.9–7.4]. A significantly elevated risk was observed for B‐cell lymphoma (OR = 2.9, 95%CI = 1.0–8.6). The highest risks were associated with diffuse large B‐cell lymphoma (OR = 7.3, 95%CI = 2.1–25.0) and marginal zone lymphoma (OR = 6.1, 95%CI = 1.1–33.9). Our results provide further evidence that HCV infection contributes to NHL risk. © 2007 Wiley‐Liss, Inc.